These findings suggest that targeting TLR9 and the cGAS-STING pathway may be a promising approach for developing new drugs against DCM, while IL-37 could serve as a therapeutic option for treating patients with DCM. This evidence concerns the gene CGAS and familial dilated cardiomyopathy.